GORE EXCLUDER AAA Endoprosthesis PXT231214Recalls & reported problems
W. L. Gore & Associates, Inc. · Class 3 · Implant
All models of GORE EXCLUDER AAA Endoprosthesis (81)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 3
- Deaths reported
- 0
- Injuries reported
- 3
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 00733132610105), received between Mar 30, 2021 and Feb 17, 2023 — classified as 3 injuries.
The most frequently reported specific device problem is “Migration” (1 report).
2 other recalls cover devices cleared under the same FDA submission (P020004); they may or may not involve this specific model.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem2
- Migration1
Patient problems
- Aneurysm2
- Aneurysm expansion1
Recent adverse event reports
The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.
InjuryFeb 17, 2023Migration; Migration
ON (B)(6) 2011, THE PATIENT UNDERWENT ENDOVASCULAR TREATMENT OF AN ABDOMINAL AORTIC ANEURYSM USING GORE® EXCLUDER® AAA ENDOPROSTHESES. ON AN UNKNOWN DATE IN 2022, CT EXAMINATION CONFIRMED DISTAL MIGRATION OF THE MAIN DEVICE WITH ANEURYSM ENLARGEMENT. ON (B)(6) 2023, REINTERVENTION WAS PERFORMED. INTRAOPERATIVE ANGIOGRAPHY DID NOT SHOW A PROXIMAL TYPE I ENDOLEAK. AS A TREATMENT FOR THE DEVICE MIGRATION WITH ANEURYSM ENLARGEMENT, CHIMNEY STENTGRAFT WAS IMPLANTED INTO THE LEFT RENAL ARTERY AND AN AORTIC EXTENDER WAS ADDITIONALLY IMPLANTED IN THE PROXIMAL SIDE. THE PATIENT TOLERATED THE PROCEDURE. REPORTEDLY THE MIGRATION WAS DUE TO AGING/DISEASE PROGRESSION.
Patient problems: Aneurysm expansion
MAUDE report 16395823 ↗InjuryNov 17, 2021Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
ON (B)(6) 2007, THIS PATIENT UNDERWENT AN ENDOVASCULAR TREATMENT FOR AN 45MM ABDOMINAL AORTIC ANEURYSM USING GORE® EXCLUDER® AAA ENDOPROSTHESES. THE TRUNK-IPSILATERAL LEG ENDOPROSTHESIS WAS IMPLANTED FROM THE RIGHT SIDE. THE CONTRALATERAL LEG AND AN ILIAC EXTENDER WERE PLACED FROM THE LEFT SIDE. A COVERED STENT (ATRIUM ADVANTA V12, 6 MM X 38 MM) WAS IMPLANTED IN THE RIGHT INTERNAL ILIAC ARTERY. AT A FOLLOW UP ON AN UNKNOWN DATE, THE ANEURYSM SAC SIZE MEASURED 24 MM. IN 2016, FOLLOW UP SHOWED ANEURYSM ENLARGEMENT. ON AN UNKNOWN DATE IN (B)(6) 2021, THE ANEURYSM MEASURED 55 MM AND AN ADDITIONAL PROCEDURE WAS INDICATED. ON (B)(6) 2021, ANGIOGRAPHY WAS PERFORMED AS A TYPE II ENDOLEAK OR DISTAL TYPE I ENDOLEAK FROM THE RIGHT SIDE WAS SUSPECTED. THE ANGIOGRAM SHOWED A DISTAL TYPE I ENDOLEAK BUT TYPE II ENDOLEAK WAS NOT OBVIOUS. TO RESOLVE THE DISTAL TYPE I ENDOLEAK, THE RIGHT INTERNAL ILIAC ARTERY WAS EMBOLIZED AND AN ADDITIONAL ILIAC EXTENDER ENDOPROSTHESIS (PLL161207J) WAS IMPLANTED INTO THE RIGHT COMMON ILIAC ARTERY. THE TREATMENT AREA WAS EXTENDED TO THE EXTERNAL ILIAC ARTERY. THE PATIENT TOLERATED THE PROCEDURE.
Patient problems: Aneurysm
MAUDE report 12830672 ↗InjuryMar 30, 2021Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
ON (B)(6) 2011, THE PATIENT UNDERWENT ENDOVASCULAR TREATMENT OF AN ABDOMINAL AORTIC ANEURYSM USING GORE® EXCLUDER® AAA ENDOPROSTHESIS. NO ISSUES WERE OBSERVED DURING THE PROCEDURE. ON AN UNKNOWN DATE, FOLLOW-UP EXAM IDENTIFIED ANEURYSM ENLARGEMENT (AMOUNT UNKNOWN). THE CAUSE OF THE ENLARGEMENT WAS REPORTEDLY A SUSPECTED PROXIMAL TYPE I ENDOLEAK, DISTAL TYPE I ENDOLEAK FROM THE RIGHT LEG (IPSILATERAL SIDE), OR TYPE II ENDOLEAK ORIGINATING FROM LUMBER ARTERIES. ON (B)(6) 2021, ADDITIONAL STENT GRAFTS WERE IMPLANTED TO EXTEND THE PROXIMAL NECK AND RIGHT LEG. COIL EMBOLIZATION WAS ALSO PERFORMED TO THE LUMBER ARTERIES. THE PATIENT TOLERATED THE PROCEDURE.
Patient problems: Aneurysm
MAUDE report 11592834 ↗
Recalls under the same FDA submission
These recalls involve devices cleared under P020004. One submission often covers many models, so check the product and lot details in each record.
- Z-0995-2020 · Jan 6, 2020 · TerminatedGORE EXCLUDER AAA Endoprosthesis
- Z-0996-2020 · Jan 6, 2020 · TerminatedGORE EXCLUDER Iliac Branch Endoprosthesis (IBE)
Other System, Endovascular Graft, Aortic Aneurysm Treatment devices
- Endurant® IIs ESBF2814C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls34 deaths254 reports
- Endurant® IIs ESBF3214C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls19 deaths173 reports
- Endurant® IIs ESBF3614C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT1 recall37 deaths214 reports
- Endurant® IIs ESBF2514C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls18 deaths136 reports
- Endurant® IIs ESBF2314C103EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls9 deaths60 reports
- RelayPro Thoracic Stent-Graft System 28-N4-34-154-34UBolton Medical Inc. · System, Endovascular Graft, Aortic Aneurysm Treatment3 recalls7 reports
- Vela Proximal Endograft System A34-34/C100-O20 VEndologix LLC · System, Endovascular Graft, Aortic Aneurysm Treatment3 deaths152 reports
- Endurant® II ETCF2828C49EMedtronic, Inc. · SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT2 recalls7 deaths44 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page